A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists-widely used in blockbuster ...

A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects against the development of ...

Osteoarthritis (OA) is one of the most prevalent conditions affecting tens of millions of U.S. adults, traditionally ...

PL8177 is a potent, selective agonist at the human melanocortin-1 receptor (MC1R), with sub-nanomolar affinity binding and EC50 functional values. Palatin data demonstrates that their oral formulation ...

LONDON (Reuters) -Jared Kushner's investment company Affinity Partners saw assets under management jump 60% last year to $4.8 billion, according to a regulatory filing, after it received a cash ...

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon. It has ...

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon. It has ...

Lilly’s candidate to activate the GLP-1, GIP, and glucagon receptors is an engineered peptide named retatrutide. Acknowledging the caveats that come with cross-trial comparisons, Phase 2 results ...

UBT251 goes a step further by also inhibiting the glucagon receptor. Eli Lilly has already got a GIP, GLP-1 and glucagon agonist into late-stage development in the form of retatrutide, which was ...

It’s an early-stage “triple agonist” that targets GLP-1, GIP, and glucagon receptors—basically mimicking key hormones to regulate blood sugar and boost insulin. Novo will pay $200 million ...

a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases. Under the license agreement ...